Last reviewed · How we verify
combined oral contraceptive
The combined oral contraceptive, developed by Jeffrey Jensen, holds a significant position in the contraceptive market as a widely marketed product. A key strength of this contraceptive is its patent protection, which is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk facing this product is the potential increase in competition following the 2028 patent expiry, which could impact its market share and revenue.
At a glance
| Generic name | combined oral contraceptive |
|---|---|
| Also known as | pill, birth control pill, COC, Apri (Reclipsen), cyclo progynova, Gynera |
| Sponsor | Jeffrey Jensen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Anxiety and Depression in Adolescent PCOS (NA)
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (PHASE1)
- A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (PHASE1)
- The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases (NA)
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY) (NA)
- Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- combined oral contraceptive CI brief — competitive landscape report
- combined oral contraceptive updates RSS · CI watch RSS
- Jeffrey Jensen portfolio CI